RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams

The FDA granted accelerated approval to VOCERYQ, the first DNA plasmid-based immunotherapy, for reducing surgeries in adults with recurrent respiratory papillomatosis (RRP). This approval introduces new plasmid and drug-device combination manufacturing demands and follows the FDA's Rare Disease Framework initiative.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.